Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 74Colorectal Neoplasms 43Rectal Neoplasms 42Stomach Neoplasms 39Triple Negative Breast Neoplasms 30Neoplasm Metastasis 19Esophageal Neoplasms 16Colonic Neoplasms 16Neoplasms 13Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Nasopharyngeal Carcinoma 11Adenocarcinoma 11Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Brain Neoplasms 6Anus Neoplasms 6Recurrence 5Neuroendocrine Tumors 5Gastrointestinal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Pathologic Complete Response 3

Interventions

durvalumab 1Surgical Procedures, Operative 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cisplatin 1Capecitabine 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Intrahepatic Cholangiocarcinoma × Capecitabine × 1 year × Clear all
NCT05265208 2025-08-06

SIROCHO

Center Eugene Marquis

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡